2 enrolling by invitation, 2 unknown. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Enrolling by invitation 2, Unknown 2 |
Follow Eosinophilic Asthma: new trials by email Literature Review of Eosinophilic Asthma trials Research Report on Eosinophilic Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fasenra: An Asthma Study Budesonide-albuterol, Benralizumab - Eosinophilic Asthma, Severe Asthma | Phase 4 | Enrolling by invitation | Endeavor Health | 40 | 2026-07-01 | 2026-09-15 |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil Mepolizumab 100 MG [Nucala] - Eosinophilic Asthma | Phase 4 | Unknown | University of Sao Paulo General Hospital | 18 | 2020-01-09 | 2020-01-14 |
| Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab". Mepolizumab, Omalizumab - Asthma, Eosinophilic Asthma | Phase 4 | Unknown | University of Newcastle, Australia | 200 | 2018-11-03 | 2020-10-14 |
Asthma (4) · Pulmonary Eosinophilia (4) · Churg-Strauss Syndrome (1)
Bronchial Diseases (4) · Eosinophilia (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Hypereosinophilic Syndrome (4) · Hypersensitivity (4) · Hypersensitivity, Immediate (4) · Immune System Diseases (4) · Leukocyte Disorders (4) · Lung Diseases (4) · Lung Diseases, Obstructive (4) · Respiratory Hypersensitivity (4) · Respiratory Tract Diseases (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Autoimmune Diseases (1)
mepolizumab (3) · Injections (1) · Omalizumab (1) · benralizumab (1)
Azienda Ospedaliero Universitaria di Cagliari (1) · Endeavor Health (1) · University of Newcastle, Australia (1) · University of Sao Paulo General Hospital (1)
Australia (1) · Brazil (1) · Italy (1) · United States (1)
Giselle Mosnaim, MD, MS (1) · Peter Wark, MBBS/PhD (1) · Rodrigo A Athanazio, MD, PhD (1)